Ovarian cancer remains one of the deadliest gynecologic malignancies. In particular, platinum-resistant ovarian cancer (PROC) is among the most challenging cancers to treat due to repeated relapses and the development of resistance to chemotherapy. The recent U.S. FDA approval of Lifyorli™ (relacorilant) in combination with nab-paclitaxel marks an important milestone in a field where therapeutic advances have long been limited. More than simply introducing a new drug, this approval is significant because it clinically validates an entirely new therapeutic concept: modulating chemotherapy resistance itself.

The standard treatment for ovarian cancer typically begins with surgery followed by platinum-based chemotherapy. While many patients initially respond well, a substantial proportion eventually experience relapse. With each recurrence, responsiveness to platinum therapy diminishes, ultimately leading to platinum resistance. At this stage, both response rates and durability of response to conventional chemotherapy decline significantly, resulting in poor clinical outcomes. Although novel modalities such as antibody-drug conjugates (ADCs), immunotherapies, and DNA damage response (DDR)-targeted agents have emerged in recent years, PROC remains an area of profound unmet medical need.

Why is PROC so difficult to treat? The primary reason is that cancer cells evolve highly complex survival mechanisms. These include enhanced DNA repair activity, alterations in the tumor microenvironment, evasion of apoptosis, metabolic reprogramming, and increased drug efflux. Many investigational therapies have shown promise in early clinical development but failed to demonstrate proof-of-concept in Phase 2 studies or were unable to advance successfully through Phase 3. This helps explain why relatively few therapies have been approved for PROC.

Against this backdrop, Lifyorli™ represents a markedly different approach from conventional anticancer therapies. Rather than directly targeting cancer cells, relacorilant inhibits cortisol–glucocorticoid receptor (GR) signaling, thereby reducing chemotherapy resistance and restoring tumor sensitivity to treatment. In other words, it is less a drug that directly kills cancer cells and more a drug that prevents cancer cells from withstanding the effects of chemotherapy.

Interestingly, this concept originated from a molecule with a long history. Corcept Therapeutics’ journey began with RU-486 (mifepristone). Originally developed as a progesterone receptor (PR) antagonist and widely known as an abortion medication, mifepristone also possesses glucocorticoid receptor antagonistic activity. Corcept leveraged this property to develop Korlym® (mifepristone) for the treatment of hyperglycemia secondary to Cushing’s syndrome. Building upon this experience, the company subsequently developed relacorilant, a selective GR antagonist designed to minimize PR-related adverse effects.

Corcept’s development story is particularly noteworthy. A small biotechnology company began with a molecule surrounded by controversy, spent decades studying cortisol biology, and ultimately established a new therapeutic paradigm in oncology. Lifyorli™ also introduced an innovative concept known as temporal pharmacology into clinical practice. Rather than being administered continuously, relacorilant is given intermittently—on the day before, the day of, and the day after chemotherapy. This schedule is specifically designed to block GR signaling during the period when cancer cells attempt to adapt to chemotherapy-induced stress. Thus, not only the magnitude of drug activity but also the timing of administration becomes an integral part of the therapeutic strategy.

Perhaps the most compelling aspect of the FDA approval was the overall survival (OS) benefit demonstrated in the pivotal study. In the Phase 3 ROSELLA trial, the combination of Lifyorli™ and nab-paclitaxel extended median OS from 11.9 months to 16.0 months (HR 0.65), a clinically meaningful improvement in PROC. Notably, the FDA placed considerable emphasis on OS outcomes rather than relying solely on progression-free survival (PFS). During the pre-NDA phase, the agency requested additional OS follow-up data. Corcept proceeded with NDA submission despite the associated risk and subsequently provided updated survival data during the review process.

Another important aspect of the review was the FDA’s rigorous assessment of statistical consistency. Clinical trials in PROC are often complicated by early treatment switching, missing imaging assessments, and complex follow-up patterns associated with repeated recurrences. The FDA independently conducted multiple censoring and sensitivity analyses and confirmed that the observed PFS benefit was not dependent on a particular analytical methodology. This review process highlights the growing importance of statistical robustness in modern oncology drug evaluations.

The emergence of Lifyorli™ may signal a broader shift in the treatment paradigm for PROC. Historically, many oncology drug development efforts have focused on directly inhibiting specific genetic alterations. However, PROC is a highly adaptive disease that cannot be fully explained by a single driver mutation. In such settings, strategies aimed at modulating resistance mechanisms may prove as important as, or even more important than, directly targeting the cancer itself.

Numerous approaches are currently under investigation in PROC, including ADCs, immunotherapies, WEE1 inhibitors, ATR inhibitors, and cell therapies. Among these, pembrolizumab-based combination therapy demonstrated encouraging results in the KEYNOTE-B96 study, extending median OS from 14.0 months to 18.2 months (HR 0.76) among patients with PD-L1 CPS ≥1, highlighting the potential of biomarker-driven immunotherapy. However, these benefits were observed in a selected subgroup representing approximately 60–80% of PROC patients. By contrast, Lifyorli™ improved median OS from 11.9 months to 16.0 months (HR 0.65) in a poorer-prognosis population of bevacizumab-pretreated PROC patients without requiring biomarker selection. Similarly, Elahere® (mirvetuximab soravtansine) has become an important treatment option for patients with FRα-positive disease, but biomarker restrictions and the emergence of resistance remain ongoing challenges.

Ultimately, the true significance of Lifyorli™ extends beyond the approval of a single new drug. Its greatest contribution may be the clinical validation of the concept of chemotherapy resensitization. For years, PROC has been characterized by a relentless cycle of recurrence and treatment resistance, with few meaningful breakthroughs. While this approval is not a complete solution, it represents a symbolic step toward a future in which cancer treatment moves beyond a simple competition of cytotoxic potency and into a new era focused on resistance modulation.

Source: The Bio (https://www.thebionews.net)